BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of BG00012
(dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer
acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS).